Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Accumulated Depreciation & Amortization (2017 - 2025)

KalVista Pharmaceuticals' Accumulated Depreciation & Amortization history spans 11 years, with the latest figure at $4.7 million for Q2 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 27.88% to $4.7 million in Q2 2025 year-over-year; TTM through Apr 2025 was $4.7 million, a 27.88% increase, with the full-year FY2025 number at $4.7 million, up 27.88% from a year prior.
  • Accumulated Depreciation & Amortization hit $4.7 million in Q2 2025 for KalVista Pharmaceuticals, up from $3.7 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for KALV hit a ceiling of $4.7 million in Q2 2025 and a floor of $2.1 million in Q2 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $3.4 million across 4 years, with a median of $3.3 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 52.7% in 2021 and later grew 25.49% in 2024.
  • Tracing KALV's Accumulated Depreciation & Amortization over 4 years: stood at $2.1 million in 2021, then skyrocketed by 41.6% to $3.0 million in 2023, then grew by 25.49% to $3.7 million in 2024, then increased by 27.88% to $4.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for KALV at $4.7 million in Q2 2025, $3.7 million in Q2 2024, and $3.0 million in Q2 2023.